Semaglutide (the active ingredient in Ozempic and Wegovy) has produced some of the most significant weight loss results ever recorded in a clinical trial. At Juvenis Medical, we pair it with a full metabolic workup — because the best outcomes happen when biology is addressed comprehensively.
The STEP clinical trial program produced some of the most compelling weight loss data ever published for a pharmaceutical intervention. These are not typical diet program numbers.
Acts on GLP-1 receptors in the brain's hunger centers, reducing appetite signals significantly. Most patients report simply wanting less food — without feeling deprived.
Food moves more slowly through the stomach, extending the feeling of fullness after meals and reducing caloric intake naturally.
Enhances insulin secretion in response to meals while reducing glucagon. Better blood sugar management supports fat metabolism and reduces cravings.
Research shows semaglutide reduces activity in brain regions associated with food reward — helping patients break compulsive or emotional eating patterns.
Semaglutide is a powerful tool — but weight loss is most successful when the underlying metabolic picture is understood and addressed comprehensively.
Discuss your weight history, previous attempts, current health, and goals. Dr. Paul assesses whether semaglutide is the right fit — and whether additional metabolic evaluation is needed.
Thyroid, insulin, fasting glucose, HbA1c, hormones, inflammation markers. Understanding your metabolic baseline ensures the protocol addresses every factor driving your weight.
Your protocol may include semaglutide plus hormone optimization, metabolic peptides, or nutrient repletion — depending on what your labs reveal. Delivered to your door from a licensed pharmacy.
Semaglutide is started at a low dose and titrated up over 12–16 weeks. Regular check-ins ensure you're tolerating the protocol well and progressing toward your goals.
Semaglutide is a GLP-1 receptor agonist — a synthetic version of the glucagon-like peptide-1 (GLP-1) your gut releases after eating. It acts on receptors in the brain and pancreas to suppress appetite, slow digestion, and improve insulin regulation. It's the active ingredient in the brand names Ozempic (diabetes) and Wegovy (weight loss).
It contains the same active molecule — semaglutide — prepared by a licensed compounding pharmacy. The therapeutic effect is the same, but compounded versions allow for flexible dosing customization and come at significantly lower cost than brand-name products.
Yes. Juvenis Medical prescribes compounded semaglutide to patients in all 50 states via telehealth, with a complete clinical evaluation. We do not prescribe it without lab work and a thorough metabolic assessment.
The most common side effects are GI-related: nausea, loose stools, and constipation — particularly during the dose escalation phase. These are typically mild to moderate and improve as the body adjusts. Starting at low doses and titrating slowly significantly reduces GI side effects.
Weight regain after stopping semaglutide is a real consideration. This is why we address the underlying metabolic factors alongside semaglutide — including hormonal optimization, insulin sensitivity, and lifestyle — so that weight loss is sustainable beyond the medication itself.
Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 agonist — it activates both GLP-1 and GIP receptors, and has shown slightly greater weight loss in head-to-head comparisons. Some patients respond better to one or the other. We evaluate both options and recommend based on your profile.
Available via telehealth nationwide. Free 15-minute consultation — find out if you're a candidate and what the full program looks like.
Book Free Consultation →